( April 12, 2024, 2:22 PM EDT) -- WASHINGTON, D. C. — A final judgment by a federal judge in Delaware directing the U. S. Food and Drug Administration to delay approval of generic rifaximin until three patents covering the antibiotic Xifaxan expire was affirmed April 11 by a three-judge panel of the Federal Circuit U. S. Court of Appeals. . . .